Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933270 · ClinicalTrials.gov registry record · NA
Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 325
- Enrollment target
NCT00933270: Completed NA study, sponsored by Abbott Medical Devices.
NCT00933270 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 325 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00933270, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 325 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, non-randomized, single arm, pivotal trial. The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA® Nitinol Stent System in treating subjects with obstructive superficial femoral artery (SFA) disease. The primary endpoint will be the primary patency of the SFA evaluated at 12 months. The outcome will be compared to a performance goal based on clinical trials of percutaneous transvenous angioplasty (PTA) alone.
Interventions
- DEVICE SUPERA® Nitinol Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT00933270 record still lists
NCT00933270 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which SUPERA® Nitinol Stent System is the first listed.
NCT00933270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00933270 about?
NCT00933270 is a clinical study titled "Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery". This is a prospective, multicenter, non-randomized, single arm, pivotal trial. The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA® Nitinol Stent System in treating subjects with obstructive superficial femoral artery (SFA) disease. The primary endpoin...
What is the current status of trial NCT00933270?
This trial is currently completed. It is a NA study. The enrollment target is 325 participants. The study started on 2009-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00933270?
The interventions under investigation include: SUPERA® Nitinol Stent System (DEVICE).
Who is sponsoring clinical trial NCT00933270?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00933270's enrollment target sits among peer trials
325 311th of 2000 higher than 1,689 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia